Monash team receives BioCurate support to develop anti-thrombotic treatment

Professor Christoph Hagemeyer in the lab. His team has received
BioCurate Proof of Concept funding for developing a therapy that
targets acute thrombosis.

Professor Christoph Hagemeyer, Head of the NanoBiotechnology Laboratory at Monash University, and his team have received Proof of Concept funding from BioCurate to develop a first-in-class antibody-based therapy that specifically targets acute thrombosis, the cause of many heart attacks, strokes and vascular blockages.

Myocardial infarction and stroke are the two single most common causes of death worldwide due, in part, to limitations with current medicines. Professor Hagemeyer’s team has developed a novel approach to inhibiting thrombosis by “uncoupling” this inhibition from adverse effects such as severe bleeding.

See story on the faculty news feed.